Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation

Transplant Infectious Disease

Volumn 17, Issue 3, 2015, Pages 342-349

  Matter Walstra, K W ^a   Greiner, M ^b   Cusini, A ^b   Schiesser, M ^b   Ledergerber, B ^b   Fehr, T ^b   Mueller, N J ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adherence; CMV disease; Cytomegalovirus; Health economics; Preemptive therapy; Prophylaxis

Indexed keywords

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT REJECTION; HEALTH CARE COST; HOSPITAL CARE; HUMAN; INFECTION PREVENTION; INTERMEDIATE RISK POPULATION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VIREMIA; ADVERSE EFFECTS; AGED; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; ECONOMICS; PROTOCOL COMPLIANCE; VIROLOGY;

ANTIVIRUS AGENT;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84930759338     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12379     Document Type: Article

References (9)

1. Kotton CN, Kumar D, Caliendo AM, et al.; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96 (4): 333-360.
2. Greiner M, Cusini A, Ruesch M, et al. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. Infection 2012; 40 (6): 669-675.
3. Hellemans R, Beutels P, Ieven M, Verpooten GA, Bosemans JL. Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience. Transpl Infect Dis 2013; 15 (1): 70-78.
4. Kielberger L, Bouda M, Jindra P, Reischig T. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res 2012; 35 (6): 407-416.
5. McGillicuddy JW, Weimert NA, Taber DJ, et al. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation 2010; 89 (10): 1218-1223.
6. Luan FL, Kommareddi M, Ojo AO. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation 2011; 91 (2): 237-244.
7. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day, 1998.
8. Conover WJ. Practical Nonparametric Statistics (3rd edn.). New York: John Wiley & Sons, 1999.
9. Faries DE, Leon AC, Haro JM, Obenchain RL, eds. Analysis of Observational Health Care Data using SAS®. Cary, NC: SAS Institute, SAS Press, 2010.